IMAGE: Lung squamous cell carcinoma

Breaking News

Key: Meeting M      Journal J      Funder F

Showing releases 1-25 out of 1256.

1 | 2 | 3 | 4 | 5 > >>

Public Release: 28-Feb-2017
Mammography trends show improved cancer detection, more biopsies
The shift from film to digital technology appears to have improved cancer detection rates for diagnostic mammography, but also has increased the abnormal interpretation rate, which may lead to more women undergoing biopsies for benign conditions, according to a new study.
NIH/National Cancer Institute

Contact: Linda Brooks
Radiological Society of North America

Public Release: 28-Feb-2017
Journal of Cancer Policy
Tanning devices cost US healthcare $343 million a year
Tanning devices cost the US $343.1 million a year in medical costs because of the skin cancers their use is associated with, according to a new study published in the Journal of Cancer Policy. In a new study, Dr. Hugh Waters and his colleagues from the University of North Carolina established how prevalent indoor tanning-related skin cancers are in the US, and calculated the costs of these diseases.

Contact: Sarah Jenkins

Public Release: 27-Feb-2017
Journal of the National Cancer Institute
Study finds biomarker for lung cancer detection in the nasal passages of smokers
A new nasal test may allow patients suspected of having lung cancer to undergo a simple swab of their nose to determine if they have the disease. Researchers at Boston University School of Medicine (BUSM) have found that a genomic biomarker in the nasal passage can accurately determine the likelihood of a lung lesion being malignant.
NIH/Early Detection Research Network, US Department of Defense, Boston University Coulter Award

Contact: Gina DiGravio
Boston University Medical Center

Public Release: 27-Feb-2017
Scientific Reports
Super resolution imaging helps determine a stem cell's future
Scientists at Rutgers and other universities have created a new way to identify the state and fate of stem cells earlier than previously possible. Understanding a stem cell's fate -- the type of cell it will eventually become -- and how far along it is in the process of development can help scientists better manipulate cells for stem cell therapy.
National Institutes of Health, National Science Foundation, NJ Stem Cell Technology CORE, Leukemia and Lymphoma Robert Arceci Scholar award

Contact: Todd B. Bates
Rutgers University

Public Release: 27-Feb-2017
Journal of Clinical Oncology
Statins do not benefit patients with lung cancer, new study shows
Cholesterol-lowering drugs used alongside chemotherapy have no effect on treatment outcomes for lung cancer patients, according to a new study.
Cancer Research UK

Contact: Colin Smith
Imperial College London

Public Release: 27-Feb-2017
npj Breast Cancer
Genetic variant of p53 gene linked to breast cancer risk in premenopausal African American women
Scientists at The Wistar Institute in collaboration with Roswell Park Cancer Institute found a significant association between a rare genetic variant of the p53 gene present in African American women and their risk of developing breast cancer in premenopausal age.
Breast Cancer Research Foundation, University Cancer Research Fund of North Carolina, US Department of Defense Breast Cancer Research Program, Era of Hope Scholar Award Program, Komen Foundation for the Cure, and others

Contact: Darien Sutton
The Wistar Institute

Public Release: 27-Feb-2017
Matching up fruit flies, mushroom toxins and human health
Some fruit flies build up tolerance to the toxin alpha-amanitin; the genetic mechanisms behind this adaptation link to an important metabolic pathway. A team from Michigan Technological University used genome-wide association mapping to draw the connections for 180 fruit fly lines.
Michigan Tech Seed Grant

Contact: Allison Mills
Michigan Technological University

Public Release: 27-Feb-2017
Clinical Cancer Research
Frequent, personalized CA125 testing may help detect ovarian cancer in high-risk women
The combined results of two ovarian cancer screening trials suggest that a personalized strategy involving frequent screening of high-risk women could improve the chance that tumors are detected at early stages when they are easier to treat.
NIH/National Cancer Institute

Contact: Katie Marquedant
Massachusetts General Hospital

Public Release: 27-Feb-2017
Nature Medicine
Molecule stops fatal pediatric brain tumor
Northwestern Medicine scientists have found a molecule that stops the growth of an aggressive pediatric brain tumor. The tumor is always fatal and primarily strikes children under 10 years old. Every other attempted therapy has failed.
NIH/National Cancer Institute

Contact: Marla Weingarten
Northwestern University

Public Release: 27-Feb-2017
The Journal of the American Osteopathic Association
Who gets sunburned? Survey finds risk is greater for young adults with melanin-rich skin
Results from a study published in The Journal of the American Osteopathic Association point to an urgent need for sunburn prevention among young adults, particularly those who have skin with higher melanin content. Researchers found a surprising correlation between reporting a red or painful sunburn lasting a day or more with being 18 to 29 years of age and not self-identifying as white.

Contact: Jeff Brennan
American Osteopathic Association

Public Release: 24-Feb-2017
The potential consequences for cancer care and cancer research of Brexit
Cancer leaders highlight main fears for patient care, treatment and research in a post-Brexit world.

Contact: Karen Watts

Public Release: 24-Feb-2017
Science Immunology
Novel 'barcode' tracking of T cells in immunotherapy patients identifies likely cancer-
A new discovery by researchers at the Fred Hutchinson Cancer Research Center in Seattle makes an important step in identifying which specific T cells within the diverse army of a person's immune system are best suited to fight cancer. The findings will be published Feb. 24 in Science Immunology.
Cancer Research Institute, Stand Up To Cancer

Contact: Molly McElroy
Fred Hutchinson Cancer Research Center

Public Release: 24-Feb-2017
Tissue Engineering: Part C
Tissue-engineered model developed to study bone-invading tumor
Researchers have used tissue engineering to create models for studying the bone-destroying activity of tumors such as the aggressive pediatric cancer Ewing's sarcoma.

Contact: Kathryn Ryan
Mary Ann Liebert, Inc./Genetic Engineering News

Public Release: 24-Feb-2017
The American Society for Blood and Marrow Transplantation (ASBMT)
New antiviral drug cuts cytomegalovirus infection and improves survival in patients
In a significant advance in improving the safety of donor stem cell transplants, a major clinical trial led by researchers at Dana-Farber Cancer Institute has shown that a novel agent can protect against the most common viral infection that patients face after transplantation.

Contact: Anne Doerr
Dana-Farber Cancer Institute

Public Release: 24-Feb-2017
Cancer Discovery
Molecular 'on switch' could point to treatments for pediatric brain tumor
Massachusetts General Hospital researchers have identified a mechanism that controls the expression of genes regulating the growth of the most aggressive form of medulloblastoma, the most common pediatric brain tumor.
A Kids' Brain Tumor Cure Foundation, Pediatric Low Grade Astrocytoma Foundation

Contact: Katie Marquedant
Massachusetts General Hospital

Public Release: 24-Feb-2017
New structural studies reveal workings of a molecular pump that ejects cancer drugs
Sometimes cells spit out things we don't want them to -- like medications. Researchers have determined the three-dimensional structure of a tiny pump that expels, among other things, chemotherapy agents. This new knowledge could lead to the design of more effective drugs.

Contact: Katherine Fenz
Rockefeller University

Public Release: 24-Feb-2017
Molecular Therapy
A novel DNA vaccine design improves chances of inducing anti-tumor immunity
Scientists at The Wistar Institute and Inovio Pharmaceuticals, Inc. have devised a novel DNA vaccine approach through molecular design to improve the immune responses elicited against one of the most important cancer antigen targets.
Inovio Pharmaceuticals, Inc. Basser Center for BRCA/Abramson Cancer CenterWeiner, W.W. Smith Charitable Trust Professorship for Cancer Research

Contact: Darien Sutton
The Wistar Institute

Public Release: 23-Feb-2017
Molecular Cell
PERK protein opens line of communication between inside and outside of the cell
PERK is known to detect protein folding errors in the cell. Researchers at the Laboratory of Cell Death Research & Therapy at KU Leuven (University of Leuven, Belgium) have now revealed a hidden perk: the protein also coordinates the communication between the inside and the outside of the cell. These findings open up new avenues for further research into treatments for cancer, Alzheimer's, and diabetes.
Research Foundation Flanders, TrainERS/Horizon 2020, Innovation by Science and Technology

Contact: Patrizia Agostinis
KU Leuven

Public Release: 23-Feb-2017
Clinical Cancer Research
Anti-aging gene identified as a promising therapeutic target for older melanoma patients
Scientists at The Wistar Institute have shown that an anti-diabetic drug can inhibit the growth of melanoma in older patients by activating an anti-aging gene that in turn inhibits a protein involved in metastatic progression and resistance to targeted therapies for the disease.
Melanoma Research Foundation, American Cancer Society, Miriam and Sheldon Adelson Research Foundation, Ira Brind Associate Professorship

Contact: Darien Sutton
The Wistar Institute

Public Release: 23-Feb-2017
Human Gene Therapy
AAV gene delivery vectors and cancer -- The debate continues
Overwhelming evidence from the biomedical literature shows that adeno-associated virus 2 (AAV2), a viral vector often used to deliver therapeutic genes, is not associated with cancer and, in fact, may protect against cancer.

Contact: Kathryn Ryan
Mary Ann Liebert, Inc./Genetic Engineering News

Public Release: 23-Feb-2017
International Journal of Cancer
Tumor protein could hold key to pancreatic cancer survival
A diagnosis of pancreatic cancer is often a death sentence because current chemotherapies have little impact on the disease.

Contact: Annie Rahilly
University of Melbourne

Public Release: 23-Feb-2017
Nature Methods
New gene sequencing software could aid in early detection, treatment of cancer
A research team from the United States and Canada has developed and successfully tested new computational software that determines whether a human DNA sample includes an epigenetic add-on linked to cancer and other adverse health conditions.
Johns Hopkins University, Ontario Institute for Cancer Research, Ontario Ministry of Research, Innovation and Science

Contact: Phil Sneiderman
Johns Hopkins University

Public Release: 23-Feb-2017
Nicotinamide riboside (vitamin B3) prevents nerve pain caused by cancer drugs
A new study in rats suggests that nicotinamide riboside (NR), a form of vitamin B3, may be useful for treating or preventing nerve pain (neuropathy) caused by chemotherapy drugs. The findings by researchers at the University of Iowa were published recently in the Journal of the International Association for the Study of Pain (PAIN) and lay the groundwork for testing whether this nutritional supplement can reduce nerve pain in cancer patients receiving chemotherapy.
The Roy J. Carver Trust

Contact: Jennifer Brown
University of Iowa Health Care

Public Release: 23-Feb-2017
Gene mutations cause leukemia, but which ones?
Watanabe-Smith's research, published today in the journal Oncotarget, sought to better understand one 'typo' in a standard leukemia assay, or test. While studying cancer biology and completing his doctorate in the lab of Brian Druker, M.D., at the OHSU Knight Cancer Institute, Watanabe-Smith encountered a new problem: an issue with the model system itself.

Contact: Amanda Gibbs
Oregon Health & Science University

Public Release: 23-Feb-2017
Researchers uncover a role for HSP90 in gene-environment interactions in humans
Researchers at the Whitehead Institute have now uncovered a role for the protein-folding chaperone HSP90 in humans, not only as a modifier of the effects of mutations, but as a mediator of the impact of the environment on the function of mutant proteins. And these effects of HSP90 can alter the course of human diseases.
Fanconi Anemia Research Fund, US Department of Defense, Harold and Leila Y. Mathers Foundation, National Institutes of Health, European Molecular Biology Organization, Human Frontier Science Program

Contact: Nicole Giese Rura
Whitehead Institute for Biomedical Research

Showing releases 1-25 out of 1256.

1 | 2 | 3 | 4 | 5 > >>

  Search News Releases